Sort by
Refine Your Search
-
be responsible for co-developing and conducting research projects and studies, writing peer-reviewed articles, and formulating new research questions for future analysis. We are looking for individuals
-
independently and collaboratively, desiring to develop and/or adapt novel approaches in biochemistry, molecules and genetics, and PhD in Neuroscience and related disciplines. However, auditory and hearing
-
-driven projects which aim to understand genome stability and acquired DNA alterations in normal cells and in cancer development. The successful applicant will primarily analyse sequencing data generated by
-
that activate kinases by removing phosphate groups, playing crucial roles in both physiological processes and various diseases. Developing drugs that target MKPs is challenging due to the nearly identical
-
cellular biology, and work in a vibrant and collaborative environment. The Alon Lab encourages career development through opportunities to lead collaborations, mentor junior trainees, and present research
-
environment. Ability to mentor and train junior team members in both clinical and molecular techniques. Commitment to maintaining high standards of laboratory safety and regulatory compliance. Experience with
-
serve as a building block for tissue engineering and regenerative therapies, with applications in stem cell development, wound healing, and cardiovascular disease treatment. Key Responsibilities Design
-
science will be rooted in basic biology and have a strong translational perspective towards developing novel therapeutics for cancer patients. Principal Investigator Background/Research: Dr. Zaidi (MD/PhD
-
Postdoctoral Associate in Computational Neuroscience at Yale The Post-Doctoral Associate will develop predictive, gene-regulatory networks linked to Parkinson’s and other neurological diseases in
-
are one of the most exciting areas of cancer biology. Many novel strategies for targeting RAS are in clinical trial, and many more are in development and are advancing to clinical trials. The Stites lab’s